EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ATRX Loss in the Development and Prognosis of Conjunctival Melanoma

Jolique A van Ipenburg, Quincy C C van den Bosch, Dion Paridaens iD, Hendrikus J Dubbink iD, Emine Kiliç, Nicole Naus, Robert M Verdijk iD, Rotterdam Ocular Melanoma Study Group

International Journal of Molecular Sciences · 20.08.2023 · 24 (16) · 12988

DOI: 10.3390/ijms241612988 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.08.2023. Verfasst von Jolique A van Ipenburg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Melanoma, Conjunctival Neoplasms, Bone Neoplasms, Skin Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Nederlands Oogheelkundig Onderzoek (SNOO). Stichting Wetenschappelijk Oogheelkundig Onderzoek (SWO)., Stichting Nederlands Oogheelkundig Onderzoek (SNOO), Stichting Wetenschappelijk Oogheelkundig Onderzoek (SWO).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic disease is linked to TERT promoter mutations in conjunctival melanomas (CM). Both TERT promoter and ATRX mutations are associated with faulty telomere maintenance. This study aimed to determine the prognostic value of ATRX loss in conjunctival melanocytic lesions. Eighty-six conjunctival melanocytic lesions from the Rotterdam Ocular Melanoma Study group were collected. ATRX status and TERT promoter status were determined using immunohistochemical staining and molecular diagnostics, respectively. None of the nevi (n = 16) and primary acquired melanosis (PAM) without atypia (n = 6) showed ATRX loss. ATRX loss was found in 2/5 PAM with atypia without CM and in 8/59 CM. No cases with a TERT promoter mutation (n = 26) showed ATRX loss. Eight/eleven metastatic CM harbored a TERT promoter mutation, two other metastatic CM showed ATRX loss and one metastatic case showed no TERT promoter/ATRX alterations. In conclusion ATRX loss and TERT promoter mutations are only found in (pre)malignant conjunctival melanocytic lesions, with most metastatic cases harboring one of these alterations, suggesting that both alterations are associated with adverse behavior. Similar to TERT promoter mutations, ATRX loss may be used as a diagnostic tool in determining whether a conjunctival melanocytic lesion is prone to having an adverse course.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaConjunctival NeoplasmsBone NeoplasmsSkin NeoplasmsHumansMelanocytesX-linked Nuclear Protein

Stichwörter der Autor:innen

conjunctival melanomageneticspathology

Substanzen

ATRX protein, humanX-linked Nuclear Protein

Autor:innen und Institutionen

  • Department of Pathology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.
  • Department of Ophthalmology, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
  • Department of Ocular Oncology, The Rotterdam Eye Hospital, Schiedamse Vest 180, 3011 BH Rotterdam, The Netherlands.
  • Department of Pathology, Section Ophthalmic Pathology, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
  • Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.

ORCID-Profile: Dion Paridaens, Hendrikus J Dubbink, Robert M Verdijk

Förderung

  • Stichting Nederlands Oogheelkundig Onderzoek (SNOO). Stichting Wetenschappelijk Oogheelkundig Onderzoek (SWO).
  • Stichting Nederlands Oogheelkundig Onderzoek (SNOO)
  • Stichting Wetenschappelijk Oogheelkundig Onderzoek (SWO)

Zitieren

APA

van Ipenburg, J. A., van den Bosch, Q. C. C., Paridaens, D., Dubbink, H. J., Kiliç, E., Naus, N., Verdijk, R. M., & Rotterdam Ocular Melanoma Study Group (2023). ATRX Loss in the Development and Prognosis of Conjunctival Melanoma. International Journal of Molecular Sciences, 24(16), 12988. https://doi.org/10.3390/ijms241612988

Vancouver

van Ipenburg JA, van den Bosch QCC, Paridaens D, Dubbink HJ, Kiliç E, Naus N, et al. ATRX Loss in the Development and Prognosis of Conjunctival Melanoma. International Journal of Molecular Sciences. 2023;24(16):12988. doi:10.3390/ijms241612988

BibTeX
@article{vanIpenburg2023,
  author = {van Ipenburg, Jolique A and van den Bosch, Quincy C C and Paridaens, Dion and Dubbink, Hendrikus J and Kiliç, Emine and Naus, Nicole and Verdijk, Robert M and Rotterdam Ocular Melanoma Study Group, Rotterdam Ocular Melanoma Study Group},
  title = {ATRX Loss in the Development and Prognosis of Conjunctival Melanoma},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {16},
  pages = {12988},
  doi = {10.3390/ijms241612988}
}
Kostenlos starten →